SomnoMed (SOM) Q1 2026 TU earnings summary

Executive summary

• Q1 FY26 revenue reached $28.7m, a 13.5% increase year-over-year (7.0% in constant currency).

• The Clayton Sleep Institute confirmed as the first US clinical site for the Rest Assure® efficacy study.

• FDA fundamentally agrees with the Rest Assure® study protocol, pending minor modifications.

• Cash balance stood at $16.5m as of 30 September 2025.

Financial highlights

• Europe revenue grew 17.1% year-over-year to $15.4m (7.1% in constant currency).

• North America revenue increased 12.4% to $11.4m (9.2% in constant currency).

• APAC revenue declined 4.6% to $1.9m (-5.0% in constant currency).

• Q1 FY26 unit sales surpassed Q1 FY25, which had benefited from backlog clearance.

Outlook and guidance

• FY26 revenue guidance reaffirmed at $119m–$126m.

• FY26 EBITDA expected between $10m and $12m.

• FY26 capex projected at $6m–$8m.